Sodium and potassium intake are modifiable determinants of hypertension in the general population but have not been studied in patients with systemic lupus erythematosus (SLE). We examined the relationship between urinary excretion of sodium and potassium, as an estimate of intake, and blood pressure in patients with SLE. We studied 178 SLE patients and 86 controls, matched for age, sex, and race. Urine sodium (Na þ ) and potassium (K þ ) were measured by flame photometry. Blood pressure was the average of two resting measurements. The associations between systolic (SBP) and diastolic blood pressures (DBP) and estimated 24-hour urinary Na þ , K þ , and Na þ :K þ ratio were tested. The estimated mean 24-hour urinary K þ excretion was lower, and the Na þ :K þ ratio was higher in patients with SLE than controls. There were no significant differences in the estimated 24-hour urinary Na þ . In patients with SLE, a higher urinary Na þ :K þ ratio was associated with higher SBP (b coefficient ¼ 4.01, p ¼ 0.023) and DBP (b coefficient ¼ 4.41, p ¼ 0.002) after adjusting for age, sex, and race. SLE patients had significantly lower estimated 24-hour urinary K þ and higher estimated 24-hour urinary Na þ : K þ ratio than controls. The urinary Na þ :K þ ratio was significantly associated with SBP and DBP.
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is associated with a five-fold increased risk of cardiovascular disease (CVD). 1 Hypertension represents an important modifiable risk factor for CVD and is more prevalent in patients with SLE than in control individuals. [2] [3] [4] [5] Traditional risk factors and disease-specific factors, such as increased disease activity, do not fully account for the increased risk of hypertension in SLE, 5, 6 and the exact mechanisms are not fully elucidated. 7 In the general population, sodium (Na þ ) and potassium (K þ ) intake are modifiable determinants of blood pressure. A large international, epidemiologic study found that for every 1 gram increase in 24-hour urinary Na þ excretion, there is an approximately 1.46 and 0.54 mm Hg increase in systolic blood pressure (SBP) and diastolic blood pressure (DBP), respectively. 8 Reduced Na þ intake, defined as less than 2.3 grams per day, reduced SBP by approximately 7-11 mm Hg in the general population. 9 Another interventional trial that reduced daily Na þ intake by 1 gram per day lowered the risk of a cardiovascular event by 25%. 10 Based on these and other observations, the American Heart Association recommends reduction of daily dietary Na þ intake to 1.5 to 2.4 grams or below per day. 11 In addition to Na þ , K þ intake also plays an important role in blood pressure and cardiovascular outcomes. Previous studies have found that for every 1 gram increase in 24-hour urinary K þ excretion, there is a reduction in SBP and DBP by 0.65 and 0.42 mm Hg, respectively. 8, 12 Further, a study with a K þ -enriched salt intervention showed a 41% reduction in CVD. 13 There are varying methods to estimate the Na þ and K þ intake in patients. First, many studies have used food diaries, an approach that is limited by patient self-report 14 and is potentially affected by recall bias. Second, other studies have measured 24-hour urine values, which are limited by patient compliance. 10, 15 Third, spot urine measurements of Na þ and K þ have been used to estimate the 24-hour urinary Na þ and K þ excretion with the validated Kawasaki formula. 16, 17 This method has been used by large epidemiologic studies. 8, 18 Recently, a large international study used spot urine Na þ and K þ values to estimate the 24-hour Na þ and K þ urinary excretion and intake using the Kawasaki formula and found a higher Na þ and a lower K þ were associated with a higher SBP. 8 Sodium intake can lead to the generation of pathogenic TH17 cells; thus, sodium has been implicated as a possible factor that exacerbates autoimmune processes. 19, 20 Furthermore, systemic inflammation can alter the renal regulation of Na þ , K þ , and water. 21 Therefore, the relationship of Na þ and K þ intake to hypertension may be stronger in SLE compared with the general population because of increased inflammation in SLE. Na þ and K þ intake and its association with blood pressure have not been studied in SLE. Patients with SLE are at high risk for adverse cardiovascular outcomes. Therefore, identifying modifiable risk factors for hypertension are of interest. We hypothesized that the urinary excretion of Na þ and K þ , as an estimate of intake, are related to blood pressure in SLE.
Materials and methods

Study design and participants
In a cross-sectional study, we evaluated 178 patients with SLE and 86 control individuals frequencymatched for age, sex, and race with available urine specimens. Patients with SLE and control participants are part of an ongoing cohort study to identify cardiovascular risk factors in SLE; this study has been described previously. 22 Briefly, patients with SLE were older than 18 years, met the classification criteria for SLE, 23 and had the disease longer than six months. They were recruited from the practices of local rheumatologists, through a Lupus Foundation newsletter, and by advertisements. Control participants had no autoimmune disease and were recruited from the patients' acquaintances, by advertisement, and from a database of volunteers maintained by the General Clinical Research Center at Vanderbilt University School of Medicine. All participants gave written informed consent prior to enrollment. The study was approved by the institutional review board of Vanderbilt University Medical Center (# 990111).
Patient assessment included a detailed review of medical records, a standardized interview, physical examination, and laboratory testing. Data on demographics, CVD risk factors, and medications were collected. Disease activity and damage were measured using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and Systemic Lupus International Collaborating Clinics Damage Index (SDI), respectively. 24, 25 The glomerular filtration rate (GFR) was estimated using the Modification of Diet in Renal Disease formula. 26 First morning urine specimens were collected and stored at -80 C. The urine samples were centrifuged at 5000 rpm at 4 C for five minutes with transfer of 100 ul of supernatant urine to a new Eppendorf Õ tube. The concentrations of urine Na þ and K þ were measured by flame photometry using an EFOX 5053 Electrolyte Analyzer from Eppendorf Õ . The Kawasaki formula, a method that incorporates age, sex, height, weight, and urinary creatinine, was used to estimate 24-hour urine Na þ and K þ excretion from the spot urine Na þ and K þ concentrations. 16 In patients with SLE, serum concentrations of interleukin-6 (IL-6), interleukin-10 (IL-10), and vascular cell adhesion protein-1 (VCAM-1) were measured using a multiplex platform (Lincoplex Inc).
Blood pressure was determined as the average of two measurements obtained five minutes apart after participants had rested quietly in the supine position for 10 minutes. Participants were considered to have hypertension if they were taking antihypertensive agents or had an SBP or DBP of at least 140 mm Hg or 90 mm Hg, respectively. Diabetes mellitus was defined as a fasting blood glucose ! 126 mg/dl and/ or use of insulin or oral medications for diabetes. Height and weight were measured and body mass index (BMI) calculated. Participants were classified as having metabolic syndrome using the modified World Health Organization definition, which requires the presence of insulin resistance and two of the following three criteria: central obesity, dyslipidemia, and hypertension. 27 
Statistical analysis
Demographic, CVD risk factors, and medication use were compared using Fisher's exact test while blood pressure and estimated 24-hour urinary Na þ , K þ , and Na þ :K þ ratio were compared using the Wilcoxon rank-sum test in patients with SLE vs. controls. The associations between SBP and DBP and the estimated 24-hour urinary Na þ , K þ , and Na þ :K þ ratio were tested using Spearman correlation and then modeled using linear regression adjusting for age, sex, and race in patients 
Results
Patients with SLE (n ¼ 178) and controls (n ¼ 86) had a similar mean age and were predominantly female, Caucasian, and well educated ( Table 1) .
Patients with SLE and controls had a similar BMI and GFR and rates of diabetes and smoking (Table 1) . However, patients with SLE had higher rates of metabolic syndrome compared to control individuals (26% vs. 12%, p ¼ 0.01).
Of the 178 SLE patients, 28% had renal involvement and 7% neurologic involvement, as defined by the American College of Rheumatology (ACR) classification criteria. 23 The mean ( AE standard deviation) SLEDAI was 4.2 AE 4.0, and the mean SDI was 1.1 AE 1.5 with 53% having any damage (SDI ! 1). For treatment, 69% of SLE patients were currently on hydroxychloroquine and 57% on a systemic corticosteroid.
Compared to controls, patients with SLE had significantly higher rates of hypertension (44% vs. 19%, p < 0.001) and antihypertensive medication use (36% vs. 12%, p < 0.001), but patients with SLE and control individuals had a similar mean SBP and DBP ( Table 2) .
The estimated 24-hour urinary Na þ excretion was similar in patients with SLE and controls (4.2 AE 1.8 vs. 4.5 AE 2.1 g, p ¼ 0.54), but the estimated 24-hour urinary K þ excretion was significantly lower in patients with SLE compared to control individuals (2.0 AE 0.7 vs. 2.4 AE 0.9 g, p < 0.001) ( Table 2 ). The estimated 24-hour urinary Na þ :K þ ratio was significantly higher in patients with SLE compared to controls (2.2 AE 0.7 vs. 1.9 AE 0.6, p ¼ 0.001) ( Figure 1 ). When comparing Sensitivity analyses were performed excluding participants taking antihypertensive medications. The estimated 24-hour urinary K þ excretion remained significantly lower and the urinary Na þ : K þ ratio remained significantly higher when excluding participants on any antihypertensive medication (p ¼ 0.003, p ¼ 0.016, respectively), diuretics (p < 0.001, p ¼ 0.005), and angiotensinconverting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) (p < 0.001, p ¼ 0.001). In addition, the estimated 24-hour urinary Na þ (4.1 AE 1.8 vs. 4.2 AE 1.8 g, p ¼ 0.86), K þ (1.9 AE 0.7 vs. 2.0 AE 0.7 g, p ¼ 0.12), and Na þ :K þ ratio (2.2 AE 0.7 vs. 2.1 AE 0.6, p ¼ 0.16) did not differ significantly among patients with SLE who were vs. were not currently receiving corticosteroids.
There were nine patients with SLE who ever had dialysis including two patients currently receiving dialysis. Exclusion of these nine patients did not affect the overall results. Patients who fulfilled (n ¼ 50) vs. did not (n ¼ 128) fulfill the renal criterion of the ACR SLE criteria 23 In patients with SLE, there were no significant associations in univariate analyses between SBP and the estimated 24-hour urinary Na þ , K þ , or the Na þ :K þ ratio ( Table 3 ). In a model adjusted for age, sex, and race, SBP was not associated with the estimated 24-hour urinary Na þ or K þ . However, SBP was associated with the urinary Na þ :K þ ratio (b coefficient (95% confidence interval (CI)) ¼ 4.01 (0.57-7.46), p ¼ 0.023).
DBP was not significantly associated with estimated 24-hour urinary Na þ and K þ . However, DBP was associated with the urinary Na þ : K þ ratio (b coefficient ¼ 3.73 (0.98-6.48), p ¼ 0.008). In a model adjusted for age, sex, and race, DBP was not associated with estimated 24-hour urinary Na þ or K þ but remained significantly associated with the urinary Na þ : K þ ratio (b coefficient ¼ 4.41 (1.71-7.11), p ¼ 0.002).
In patients with SLE, SLEDAI was not significantly associated with SBP, (p ¼ 0.64) DBP, (p ¼ 0.21) the estimated 24-hour urinary Na þ , (p ¼ 0.64), K þ (p ¼ 0.08), or the Na þ :K þ ratio (p ¼ 0.57). SDI was associated with SBP (rho ¼0.15, p ¼ 0.04) but not with DBP (rho ¼ 0.10, p ¼ 0.17). SDI was not associated with the estimated 24-hour urinary Na þ (p ¼ 0.91), K þ (p ¼ 0.49), or the Na þ :K þ ratio (p ¼ 0.24).
Inflammatory cytokines IL-10 and IL-6 were not significantly associated with SBP or DBP (Table 4 ). However, VCAM-1 was associated with SBP (rho ¼ 0.21, p ¼ 0.006) but not DBP. IL-6 and VCAM-1 were not associated with the estimated 24-hour urinary Na þ , K þ , or the Na þ :K þ ratio. However, IL-10 was negatively correlated with the Na þ :K þ ratio (rho ¼ À0.196, p ¼ 0.0091).
Discussion
There are two main findings of this study. First, patients with SLE had a significantly lower estimated 24-hour urinary K þ and a higher estimated 24-hour urinary Na þ :K þ ratio compared to controls. Second, the estimated 24-hour urinary Na þ :K þ ratio was significantly associated with SBP and DBP in patients with SLE, even after adjustment for age, sex, and race. Specifically, for every one point increase in the Na þ :K þ ratio, there was an approximately 4 mm Hg increase both in SBP and DBP in patients with SLE. Our findings are important because patients with SLE have higher rates of hypertension, and Na þ and K þ intake are potentially modifiable risk factors for hypertension. Interestingly, patients with SLE had a significantly lower estimated 24-hour urinary K þ compared to control individuals. Causes of low urinary K þ include renal disease and medications such as diuretics. Sensitivity analyses that accounted for antihypertensive medications, including diuretics, did not show that these medications were driving the lower K þ in the SLE patients. Further, excluding patients with a previous history of dialysis did not significantly affect the K þ . Even though the lower K þ was not statistically associated with a higher SBP and DBP in this study, the lower K þ may be clinically important, as it has been associated with hypertension, CVD, and death in the general population. [13] [14] [15] Future studies should consider the potential role of K þ in investigating hypertension and CVD outcomes in SLE patients.
In this study, patients with SLE were twice as likely to have hypertension compared to control participants frequency-matched on age, sex, and race. This finding agrees with another cohort study in which patients with SLE were also twice as likely to have hypertension compared to controls. 2 While patients with SLE in our study had higher rates of hypertension vs. controls, they had a similar mean SBP and DBP compared to control individuals, which indicates well-controlled blood pressures on their current antihypertensive medications, based on the mean SBP and DBP within the normotensive range.
The pathophysiology of hypertension in SLE is complex and not fully understood. Potential mechanisms that have been proposed are an increased systemic vascular resistance and an altered pressure-natriuresis relationship in the kidneys whereby higher pressures are needed for sodium excretion. 7 Recent work highlights the role of inflammation in hypertension, which may be pertinent to understanding the mechanisms of hypertension in SLE. Systemic inflammation can alter the renal handling of Na þ and water, which may implicate Na þ and K þ in the pathophysiology of hypertension. 21 There is evidence both for innate and adaptive immune cells infiltrating, releasing cytokines, and causing oxidative stress in the kidney and vasculature to elevate blood pressure and cause organ damage. 21 In the vasculature, macrophages and monocytes infiltrate the adventitia to promote oxidative injury, endothelial dysfunction, vascular remodeling, and arterial stiffness, which contribute to increased systemic vascular resistance. 21 In the kidney, inflammatory cytokines elicit fibrosis, glomerular damage, and alterations in sodium transporter expression. 21 Specifically, IL-6 and interferon gamma (IFNg) in animal models promote angiotensinogen secretion that increases angiotensin II release as well as increases expression of sodium transporters that increases distal sodium reabsorption. [28] [29] [30] In contrast, the anti-inflammatory cytokine IL-10 may have a protective role in hypertension by modulating endothelial dysfunction. 31 In summary, inflammatory cytokines can affect both the local reninangiotensin system and the expression of renal sodium transporters to affect sodium and water balance. Therefore, inflammatory cytokines may affect renal Na þ handling, which could contribute to the increased prevalence of hypertension in SLE.
In our study, IL-10 was negatively correlated with the Na þ :K þ ratio but not associated with SBP, DBP, the estimated 24-hour urinary Na þ , or K þ . The negative correlation could be explained as some studies suggest that IL-10 may have a protective role in hypertension. 31 IL-6 was not associated with SBP, DBP, the estimated 24 hour urinary Na, þ K þ , or the Na þ :K þ ratio. While increased IL-6 levels have been associated with hypertension in animal models and humans, it is not clear if there is an association with hypertension in patients with SLE. 21 IL-6 levels may fluctuate in patients with SLE as well as be reduced by immunosuppressive medications, which may explain why our cross-sectional study did not detect an association. Future longitudinal studies are needed to study the association between these cytokines and blood pressure in patients with SLE.
Our study has several limitations. First, this is a cross-sectional study with a one-time spot urine collection, so causality between urinary Na þ and K þ Table 4 Association of inflammatory cytokines with blood pressure and estimated 24-hour urinary Na þ , K þ , and Na þ : K þ ratio in systemic lupus erythematosus (SLE) patients
Interleukin-6
Interleukin-10
Vascular cell adhesion protein-1 excretion with blood pressure cannot be inferred. We also do not have longitudinal data on the blood pressure and urinary values that could be helpful in understanding the variability of these measures.
As the cohort was initially designed to identify cardiovascular risk factors in SLE, there were half as many controls as cases. Controls were frequency-matched for age, sex, and race and not for other variables such as hypertension so that the contribution of such variables to differences in cardiovascular risk in SLE and control groups could be studied. Second, we used the Kawasaki formula to estimate a 24-hour Na þ and K þ excretion from the spot urine Na þ and K þ measurements. We then used the estimated 24-hour Na þ and K þ excretion as a surrogate for dietary intake. While this method has limitations as an estimation of the dietary intake of Na þ and K þ , it does provide some advantages over other collection methods. Namely, using this Kawasaki formula reduces recall bias from patients reporting dietary intake and is more convenient as well as perhaps more accurate than 24-hour urine collections, particularly if patients are not reliable in their collections. Estimated 24-hour urinary Na þ and K þ excretion values obtained from the Kawasaki formula correlate with 24-hour urinary Na þ and K þ values. 16, 32 Further, the Kawasaki formula has been validated both in the general population and in patients with hypertension 17, 32 and used in large international studies. 8, 18, [33] [34] [35] Renal disease may have affected the estimated urinary values. SLE patients with the renal criterion of the ACR SLE criteria 23 had a lower estimated urinary K þ but similar Na þ and Na þ :K þ ratio compared to the SLE patients without the renal criterion. We hypothesize that recommended diet changes in patients with a history of renal disease may have contributed to the lower K þ in the renal criterion group.
In conclusion, patients with SLE had a significantly lower estimated 24-hour urinary K þ and higher estimated 24-hour urinary Na þ :K þ ratio than control individuals. The estimated 24-hour urinary Na þ :K þ ratio was significantly associated with SBP and DBP in patients with SLE. This study highlights the potential role of Na þ and K þ intake to hypertension in SLE and represents an initial step in exploring the mechanisms of hypertension in SLE. Future prospective and longitudinal studies will be helpful to characterize the effect of modifications in the Na þ and K þ intake on hypertension in patients with SLE. As hypertension is a major contributor to adverse cardiovascular outcomes in SLE, identifying modifiable risk factors for hypertension is important in reducing cardiovascular morbidity and mortality.
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